Skip to main content
Premium Trial:

Request an Annual Quote

Karen Eastham and Ronald Matricaria

Premium

Karen Eastham has been appointed to the board of directors of Illumina, the company announced last week.

She is executive vice president, COO, and a member of the board of trustees of the Burnham Institute. Prior to that, she was senior vice president and CFO of Diversa.

Eastham holds an MBA and a BS from Indiana University. She also serves on the boards of directors of Tercica, Oncosis/Cyntellect, and Salmedix, as well on the board of UCSD Athena.


Ronald Matricaria has joined the board of directors of Invitrogen, replacing William Mercer, who is retiring.

Matricaria is the former chairman and CEO of St. Jude Medical. Before his term at St. Jude, he spent 23 years at Eli Lilly, where his last position was executive vice president of the pharmaceutical division and president of its North American operations. He also had held the position of CEO at Lilly subsidiary Cardiac Pacemakers.

Matricaria also serves on the boards of directors of Cyberonics, VistaCare, CardioDynamics, and is chairman of the board of Haemonetics.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.